Belimumab Treatment for Lupus Nephritis: A Narrative Review

Abstract

Background: Lupus nephritis (LN) is a common complication in Systemic lupus erythematosus (SLE) patients. Treatment of lupus nephritis ranges from initial management with lifestyle changes and medications like corticosteroids for mild cases to the most intensive approach involving high-dose immunosuppressive therapy and potentially kidney transplantation for severe cases. A monoclonal antibody, called belimumab, that targets the B-lymphocyte stimulator (BLyS) has shown promise as a treatment for LN. This narrative review endeavors to provide a comprehensive overview of how belimumab functions, its efficacy, and its safety considerations when utilized in the treatment of lupus nephritis. Methodology: A literature review was conducted on various databases, including PubMed, Medline, Science Direct, and Google Scholar, using the following terms: “lupus nephritis”, “safety”, “efficacy” and “belimumab”. All articles considered relevant were included. No limitations were imposed on the publication date. Results: Improvements in clinical response and a decrease in glucocorticoid dosage were observed in patients with lupus nephritis treated with belimumab, according to our narrative review. Additionally, significantly higher rates of renal response were proven with the combination of belimumab and standard therapy. Trials showed similar safety profiles for belimumab added to standard therapy versus standard therapy alone. Conclusion: By focusing on B-cell dysregulation and lowering autoimmune response, belimumab provides a promising treatment approach for lupus nephritis. Its potential as an additional treatment for LN is supported by its effectiveness in enhancing renal responsiveness and overall disease activity as well as by its positive safety profile.